(RFL) Rafael Holdings, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RFL) Rafael Holdings, Inc. Complete Analysis Pack
See the Bigger Picture
This Rafael Holdings, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
CPI-613 devimistat, Phase III pancreatic cancer
CPI-613 (devimistat) is Rafael Holdings, Inc.'s lead oncology asset and the closest fit to a Star, because it is in a pivotal Phase III registrational study for advanced pancreatic cancer, a disease with about a 13% 5-year relative survival rate in the U.S. If the study succeeds, it could become Rafael Holdings, Inc.'s first major commercial value driver and move the asset from pipeline risk to revenue potential.
CPI-613 devimistat, Phase III AML
CPI-613 (devimistat) is Rafael Holdings, Inc.'s star asset: it is in Phase III for relapsed/refractory acute myeloid leukemia and also in a second Phase III registrational study, giving the company two late-stage shots from one program.
That makes it the highest-upside part of the portfolio, even though it is still pre-revenue. One asset, two approval paths, and very high binary risk.
Rafael Pharmaceuticals late-stage oncology platform
Rafael Pharmaceuticals’ devimistat platform targets cancer metabolism through a distinct lipoate-based mechanism, and late-stage oncology assets draw the most strategic value because they sit closest to approval. In Rafael Holdings, Inc.’s FY2025 filing, the company still reported $0 product revenue, so this program remains the main growth option. If a Phase 3 win lands, the upside can re-rate fast.
Two pivotal registrational trials
By end-2025, Rafael Holdings had 2 Phase III registrational studies running for devimistat, its most advanced program. That late-stage progress is the main reason the asset set sits in the Star bucket, because Phase III trials are the last major step before possible approval and can move market value fast.
2 Phase III studies active
Devimistat is the lead Star asset
Late-stage data is the key catalyst
Metabolic-cancer therapeutic thesis
Rafael Holdings, Inc. centers its pharma arm on a metabolic-cancer thesis: target the fuel differences between healthy and malignant cells. That idea is the core of the division and, if validated clinically, it can support more than one cancer use case. The risk is binary: in FY2025 the value is still driven by R&D, not sales.
- Core thesis: metabolism-based selectivity
- Upside: multi-indication platform
- Key risk: clinical translation
Rafael Holdings’ Star: CPI-613 Drives Late-Stage Oncology Upside
Stars in Rafael Holdings, Inc. are led by CPI-613 (devimistat), the company’s main late-stage oncology asset. In FY2025, Rafael Holdings, Inc. still had $0 product revenue, so the upside is tied to clinical success, not sales. With 2 Phase III registrational studies active by end-2025, it is the clearest Star candidate.
| Metric | FY2025 |
|---|---|
| Product revenue | $0 |
| Phase III studies | 2 |
| Star asset | CPI-613 |
What is included in the product
Detailed Word Document
BCG Matrix view of Rafael Holdings, Inc.: maps its units into Stars, Cash Cows, Question Marks, and Dogs to guide invest/hold/divest decisions.
Editable Excel File
One-page Rafael Holdings BCG Matrix easing portfolio clarity for faster, cleaner decisions
Reference Sources
Supports confidence in Rafael Holdings, Inc. analysis by clearly tracing key claims to credible reference sources for faster, better decisions.
Cash Cows
Newark office complex
Rafael Holdings, Inc.'s Newark office complex is a mature, leased asset in Newark, New Jersey, so it fits the Cash Cow bucket. The property is the clearest recurring cash-flow source in the portfolio, with office rent tied to stable occupancy rather than growth. This is a classic low-growth, income-generating BCG profile.
800-space public parking facility
Rafael Holdings, Inc.’s 800-space public parking facility adds fee-based income next to the office building, giving the real estate segment a steady cash stream. Parking revenue is usually more stable than drug-development cash flow, with daily occupancy and monthly lease fees supporting repeat income. That makes the asset a clear Cash Cow in the BCG Matrix, helping fund broader operations.
United States commercial real estate
Rafael Holdings, Inc.'s U.S. commercial real estate is a Cash Cow: mature, low-growth assets that can still throw off rent tied to occupancy. U.S. office vacancy stayed near 19% in 2025, so returns are more about steady lease income and asset management than expansion. This is cash-generating, not a growth engine.
Israel real estate holdings
Rafael Holdings, Inc. keeps commercial real estate assets in Israel that fit the Cash Cows bucket: mature, capital-heavy holdings with limited growth but steady income potential. In fiscal 2025, this segment continued to serve as a cash-generating base rather than a growth driver, so the play is to milk cash flow and preserve occupancy, rent collection, and asset value.
- Commercial real estate in Israel
- Mature, low-growth asset base
- Steady rental cash flow focus
- Supports the portfolio’s income engine
Real estate segment revenue base
Rafael Holdings, Inc.’s real estate segment is its only clearly recurring cash source, with rental and parking income helping fund pharma R&D burn. In BCG terms, that makes it the portfolio’s Cash Cow: a mature asset that can keep producing cash even as the healthcare side stays investment-heavy. The latest filings still show the segment as the financial anchor for the rest of the group.
- Stable rent and parking cash flow
- Offsets pharmaceutical R&D burn
- Supports the wider portfolio
- Best fit: BCG Cash Cow
Rafael Holdings’ Cash Cow Keeps Cash Flow Steady Despite Weak Office Growth
Rafael Holdings, Inc.’s Cash Cow is its mature real estate base: Newark office rent, 800-space parking income, and Israel property leases. In fiscal 2025, this segment stayed the group’s main recurring cash source, while U.S. office vacancy near 19% kept growth weak and income the focus.
| Cash Cow asset | 2025 signal |
|---|---|
| Newark office | Stable lease income |
| Parking | 800 spaces, fee cash flow |
| Israel real estate | Steady rental base |
Get Your Copy
Rafael Holdings, Inc. Reference Sources
The Rafael Holdings, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. There are no placeholders, watermarks, or demo sections—just the complete, professionally formatted file. Once purchased, it’s ready for immediate download, use, and presentation.
Dogs
No marketed pharmaceuticals
As of fiscal 2025, Rafael Holdings, Inc. had no approved drug products on sale, so its pharma unit still had no commercial revenue stream. That puts the unit in a weak current-share spot in BCG terms: it is not yet a cash cow or star, but a pure pipeline bet. With $0 product sales and no marketed pharma portfolio, the segment fits the "Dogs" profile today.
Pre-revenue clinical spend
Rafael Holdings’ pharmaceutical work is still pre-revenue, so clinical spend burns cash before it can bring any in. With zero commercial drug sales and work still in development and registrational testing, this Dogs bucket stays a cash trap until approval.
Corporate headquarters overhead
According to Rafael Holdings, Inc.'s FY2025 filing, its Newark, New Jersey headquarters supports public-company overhead, not market share or product sales. Those administrative costs sit above the portfolio and can dilute total returns because they do not scale with revenue. In BCG terms, this is cost drag, not a growth engine.
Minority strategic investments
In FY2025, Rafael Holdings kept minority strategic stakes in early-stage and clinical pharmaceutical companies, which gives little control and no steady cash flow. These positions only matter if a clinical readout, IPO, sale, or license deal turns them into a value event; without that, they can sit as Dogs. Clinical assets often need Phase 2 or Phase 3 wins before markets reprice them.
- Low control, high binary risk
- Value depends on exits
- No exit, no lift
Unproven noncore bets
Anything outside Rafael Holdings, Inc.'s devimistat focus is still unproven at scale in FY2025/2026. Small, noncommercial holdings can sit on the balance sheet and consume capital while adding little or no cash flow, so they do not change the core BCG picture.
These Dogs fit pruning logic: if an asset does not advance devimistat or create a near-term monetization path, it is better cut than kept.
- Low scale, low cash return
- Capital tied up, not recycled
- Prune unless it advances growth
Rafael Holdings Stays Pre-Revenue, Cash-Burning in FY2025
In FY2025, Rafael Holdings, Inc. still had no approved pharma product sales, so the Dogs bucket remains pre-revenue and cash-burning. Zero commercial revenue means no market share leverage yet, and minority stakes in early assets still depend on a binary exit.
| Metric | FY2025 |
|---|---|
| Pharma product sales | $0 |
| Approved products | 0 |
| Cash flow profile | Burn stage |
Question Marks
Early-stage pharmaceutical holdings
Rafael Holdings, Inc. explicitly holds stakes in early-stage pharma companies, and these are classic Question Marks in the BCG Matrix: high upside, but near-zero current market share because they are still pre-commercial. Drug development is a tough bet, too; only about 10% of drug candidates that enter clinical testing reach approval, so these assets can swing hard in value. That mix of low share and high potential fits Question Marks exactly.
New oncology assets
Rafael Holdings, Inc.’s new oncology assets are still Question Marks: beyond devimistat, the other programs are at much earlier stages, so there is no real revenue base yet. The market can be large, but these assets still need capital and proof-of-concept data before they can move into a stronger BCG position. Until then, they stay high-upside, high-risk bets.
Pipeline expansion beyond Phase III
Rafael Holdings, Inc.’s next growth step is pipeline expansion beyond Phase III, where new indications or new molecules would begin with low market share and unclear uptake. That makes this the riskiest BCG "Question Mark" zone: spending rises before revenue is proven, so cash burn and trial success rates matter most. If a new asset clears late-stage hurdles, it can shift from a question mark to a star; if not, value can fade fast.
Commercial launch pathway
Devimistat is still pre-commercial: it needs regulatory success, then pricing, reimbursement, and payer access before any sales can start. With no approved launch base, its near-term value is still option-like, not recurring revenue.
- No FDA approval yet
- No sales base today
- Revenue starts after access
Pharma partnership optionality
Rafael Holdings, Inc.’s pharma partnership optionality fits a Question Mark: out-licensing could speed development and widen market access, but until a signed deal exists it is only pipeline value, not cash flow. That matters because execution is still unproven, and the asset only turns into a real revenue driver after a partner commits capital and milestones.
- Deal signed: optionality becomes monetization.
- No deal yet: no cash generation.
- Growth case exists, but proof is missing.
Rafael Holdings’ Drug Pipeline: High Upside, High Pre-Commercial Risk
Rafael Holdings, Inc.’s Question Marks are still pre-commercial: no FDA approval, no sales base, and each program still needs proof-of-concept plus capital. That fits BCG Question Marks because upside is real, but cash use comes before revenue. In drug development, only about 10% of clinical candidates reach approval, so the risk is high.
| Metric | FY2025/FY2026 view |
|---|---|
| FDA approval | None |
| Revenue base | None |
| Clinical success rate | ~10% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.